Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6525
    +0.0025 (+0.39%)
     

  • OIL

    83.19
    +0.38 (+0.46%)
     

  • GOLD

    2,339.10
    +0.70 (+0.03%)
     

  • Bitcoin AUD

    98,302.62
    -3,794.08 (-3.72%)
     

  • CMC Crypto 200

    1,362.69
    -19.89 (-1.44%)
     

  • AUD/EUR

    0.6082
    +0.0012 (+0.19%)
     

  • AUD/NZD

    1.0946
    +0.0004 (+0.04%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,083.19
    +42.81 (+0.53%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,014.14
    -74.56 (-0.41%)
     

  • Hang Seng

    17,269.04
    +67.77 (+0.39%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

Imara, Inc.
·1-min read

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 6, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and review recent business highlights.

A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 6499377. A replay of the webcast will be archived on the Imara website following the presentation.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com